We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Sunshine Biopharma Inc (SBFM) USD0.001

Sell:$0.0545 Buy:$0.055 Change: No change
Market closed |  Prices as at close on 1 March 2024 | Switch to live prices |
Sell:$0.0545
Buy:$0.055
Change: No change
Market closed |  Prices as at close on 1 March 2024 | Switch to live prices |
Sell:$0.0545
Buy:$0.055
Change: No change
Market closed |  Prices as at close on 1 March 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Sunshine Biopharma, Inc. is a Canada-based pharmaceutical company. The Company offers and researches life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. The Company has 27 additional generic prescription drugs. In addition, the Company is engaged in the development of various proprietary drugs, including Adva-27a, K1.1 mRNA and SBFM-PL4. Adva-27a is a small chemotherapy molecule targeting pancreatic cancer. The K1.1 mRNA is developed for liver cancer. SBFM-PL4 is an anti-coronavirus compound. The Company operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). It also operates two wholly owned subsidiaries: NoraPharma Inc., which has a portfolio consisting of 50 generic prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells non-prescription over-the-counter (OTC) products.

Contact details

Address:
6500 TRANS-CANADA HIGHWAY, 4TH FLOOR
POINTE-CLAIRE
H9R 0A5
Canada
Telephone:
+1 (514) 4266161
Website:
https://www.sunshinebiopharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
SBFM
ISIN:
US8677814035
Market cap:
$3.02 million
Shares in issue:
54.45 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Steve Slilaty
    Chairman of the Board, President, Chief Executive Officer
  • Camille Sebaaly
    Chief Financial Officer, Secretary
  • Marc Beaudoin
    Chief Operating Officer
  • Abderrazzak Merzouki
    Chief Science Officer, Director
  • Malek Chamoun
    Chief Development Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.